(19)
(11) EP 4 237 566 A2

(12)

(88) Date of publication A3:
21.07.2022

(43) Date of publication:
06.09.2023 Bulletin 2023/36

(21) Application number: 21887430.3

(22) Date of filing: 27.10.2021
(51) International Patent Classification (IPC): 
C12N 15/86(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 5/0638; C12N 2510/00; C12N 15/86; C12N 2740/16043; C12N 2710/10343; A61K 35/761; A61P 35/00
(86) International application number:
PCT/US2021/056829
(87) International publication number:
WO 2022/093944 (05.05.2022 Gazette 2022/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 27.10.2020 US 202063106215 P

(71) Applicants:
  • H. Lee Moffitt Cancer Center & Research Institute, Inc.
    Tampa, Florida 33612 (US)
  • Memgen, Inc.
    Houston, TX 77046 (US)

(72) Inventors:
  • BEG, Amer
    Tampa, Florida 33647 (US)
  • CANTWELL, Mark J.
    Meadow Vista, California 95722 (US)

(74) Representative: Lavoix 
Bayerstraße 83
80335 München
80335 München (DE)

   


(54) ONCOLYTIC VIRUS BOOSTS T CELL RESPONSE FOR EFFECTIVE TIL THERAPY